STAT6 and hepatocellular carcinoma: One study supported by Codiak BioSciences company evaluated the exosomes loaded with CDK-004 (exoASO-STAT6)’s safety, tolerability, and initial antitumor activity in patients with advanced hepatocellular carcinoma (HCC) and patients with liver metastases from either primary gastric cancer or colorectal cancer (NCT05375604).